Subtype
Digestive System Carcinoma
CI-CAN-00000812Explore in graph →
2,124 active trials27 approved drugs139 evidence items
- NCIt
- C96963
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000812Explore in graph →
Clinical trials
7,545 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (885)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07226856 | BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma | recruiting | Phase 2 | 43 | Mayo ClinicOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT06790602 | Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma(SWITCH) | recruiting | Phase 2 | 43 | University of California, San DiegoOTHER | 1 | Jun 8, 2026 |
| clinicaltrials |
| NCT07145450 | Master Protocol of TCR-modified T Cell Therapy Targeting HLA-restricted KRAS Antigen Administered in Adult Patients With Metastatic or Locally Advanced PDAC | recruiting | Phase 1 / Phase 2 | 96 | Anocca ABOTHER_GOV | 4 | Jun 8, 2026 | clinicaltrials |
| NCT07623642 | A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors. | not yet recruiting | Phase 2 | 227 | GV20 TherapeuticsINDUSTRY | 1 | Jun 8, 2026 | clinicaltrials |
| NCT06307548 | Fluorescence Image Guided Surgery Followed by Intraoperative Photodynamic Therapy for Improving Local Tumor Control in Patients With Locally Advanced or Recurrent Colorectal Cancer | recruiting | Phase 1 / Phase 2 | 21 | Roswell Park Cancer InstituteOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT06339619 | Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur, Gimeracil and Oteracil Potassium Capsules for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 32 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07627711 | Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma(DUAL-NK-PDAC) | recruiting | Phase 1 / Phase 2 | 42 | Beijing BiotechINDUSTRY | 1 | Jun 4, 2026 | clinicaltrials |
| NCT06770452 | HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients | recruiting | Phase 2 | 133 | Zhejiang UniversityOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07076121 | A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30) | active not recruiting | Phase 2 / Phase 3 | 470 | Bristol-Myers SquibbINDUSTRY | 36 | Jun 3, 2026 | clinicaltrials |
| NCT07483554 | IBI343 in Combination Therapy for Advanced Malignant Solid Tumors | recruiting | Phase 2 | 389 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07621562 | Tafolecimab Combined With Sintilimab and SOX in the Treatment of pMMR/MSS Gastric Cancer | not yet recruiting | Phase 2 | 30 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT03801083 | Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers | active not recruiting | Phase 2 | 4 | Udai KammulaOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05507632 | Donafenib Plus Sintilimab in Combination With TACE in Patients With Unresectable Hepatocellular Carcinoma | active not recruiting | Phase 2 | 48 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT07036380 | MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma(TACTIC) | recruiting | Phase 2 | 75 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT07618910 | Retlirafusp Alfa Plus Chemotherapy as Neoadjuvant Therapy for Thoracic ESCC | not yet recruiting | Phase 2 | 33 | Tang-Du HospitalOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT06598007 | A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 78 | Crossignal Therapeutics, Inc.INDUSTRY | 1 | May 29, 2026 | clinicaltrials |
| NCT06851663 | Trop2-targeted immunoPET Imaging of Solid Tumors | recruiting | Phase 2 / Phase 3 | 400 | RenJi HospitalOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT07223047 | A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies | recruiting | Phase 1 / Phase 2 | 252 | Bristol-Myers SquibbINDUSTRY | 3 | May 28, 2026 | clinicaltrials |
| NCT07452601 | Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC | recruiting | Phase 2 | 90 | Tang-Du HospitalOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT07483359 | Conversion Therapy With FOLFOX-HAIC Plus Lenvatinib And Tislelizumab For Hepatocellular Carcinoma With Vp3 Portal Vein Tumor Thrombus(CONV3RSION) | recruiting | Phase 2 | 38 | First Hospital of China Medical UniversityOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT07610629 | Retlirafusp Alfa Combined With Apatinib and Nab-Paclitaxel as Second-line Treatment for Gastric or Gastroesophageal Junction Cancer(RA-A-NP) | not yet recruiting | Phase 2 | 50 | Henan Cancer HospitalOTHER_GOV | 1 | May 28, 2026 | clinicaltrials |
| NCT05910827 | A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers | recruiting | Phase 1 / Phase 2 | 398 | Hummingbird BioscienceINDUSTRY | 5 | May 27, 2026 | clinicaltrials |
| NCT07495579 | Lenvatinib or Regorafenib for Advanced Hepatocellular Carcinoma After Immunotherapy (REVIVE)(REVIVE) | not yet recruiting | Phase 2 | 146 | Asan Medical CenterOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT04982653 | Short Stitch Versus Traditional Suture for the Prevention of Incisional Hernia After Open Hepatectomy | recruiting | Phase 2 | 140 | M.D. Anderson Cancer CenterOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT05620771 | Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk | recruiting | Phase 2 | 200 | Northwestern UniversityOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT05977998 | A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology | recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT06067438 | Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer | recruiting | Phase 2 | 90 | OHSU Knight Cancer InstituteOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07462143 | A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer | recruiting | Phase 2 / Phase 3 | 80 | RemeGen Co., Ltd.INDUSTRY | 1 | May 22, 2026 | clinicaltrials |
| NCT07493668 | Fostrox Plus Lenvatinib vs Lenvatinib in Advanced Hepatocellular Carcinoma After First-line Immunotherapy(FLEX-HCC) | recruiting | Phase 2 | 80 | CHA UniversityOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07603349 | Adaptive Adjuvant Therapy After Neoadjuvant Therapy and Gastrectomy for Gastric or Gastroesophageal Junction Adenocarcinoma | not yet recruiting | Phase 2 / Phase 3 | 405 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07205731 | Phase II Study Evaluating Safety and Efficacy of Tislelizumab for Elderly Patients Unfit for Chemotherapy, With Advanced Esophageal Squamous-cell Carcinoma(SAFE ESO) | recruiting | Phase 2 | 95 | University Hospital, Clermont-FerrandOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT07598318 | Study of Becotatug Vedotin Added to Standard Treatment for Advanced Bile Duct Cancer With EGFR Mutations | not yet recruiting | Phase 2 / Phase 3 | 164 | Sir Run Run Shaw HospitalOTHER | 0 | May 20, 2026 | clinicaltrials |
| NCT05431270 | Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study) | recruiting | Phase 1 / Phase 2 | 40 | Phanes TherapeuticsINDUSTRY | 1 | May 19, 2026 | clinicaltrials |
| NCT05468359 | Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients | recruiting | Phase 1 / Phase 2 | 64 | St. Jude Children's Research HospitalOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT06503146 | 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection | recruiting | Phase 2 | 320 | National Cancer Institute (NCI)NIH | 1 | May 19, 2026 | clinicaltrials |
| NCT06904378 | ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma | recruiting | Phase 1 / Phase 2 | 61 | Washington University School of MedicineOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT07280377 | A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab(GOBLET) | active not recruiting | Phase 1 / Phase 2 | 122 | Oncolytics BiotechINDUSTRY | 1 | May 19, 2026 | clinicaltrials |
| NCT07595172 | NALIRIFOX+Adebrelimab+PULSAR for Advanced Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 55 | West China HospitalOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT07595770 | Adebrelimab Combined With Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma(ANCRE) | recruiting | Phase 2 | 37 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT04421820 | BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 220 | Bold Therapeutics, Inc.INDUSTRY | 7 | May 18, 2026 | clinicaltrials |
| NCT04042831 | Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations | active not recruiting | Phase 2 | 32 | Academic and Community Cancer Research UnitedOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT05379985 | Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS | recruiting | Phase 1 / Phase 2 | 754 | Revolution Medicines, Inc.INDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT06251973 | A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer | active not recruiting | Phase 2 | 20 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT07589517 | Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer(DUO-CRC-NK-111) | recruiting | Phase 1 / Phase 2 | 48 | Beijing BiotechINDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT07590336 | 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma(NYHCC) | not yet recruiting | Phase 1 / Phase 2 | 100 | Peking Union Medical College HospitalOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT04789486 | Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 100 | Dana-Farber Cancer InstituteOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT05988918 | Multicenter Trial of ESK981 in Patients With Select Solid Tumors | active not recruiting | Phase 2 | 17 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT06922591 | Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients | recruiting | Phase 1 / Phase 2 | 183 | Tango Therapeutics, Inc.INDUSTRY | 1 | May 14, 2026 | clinicaltrials |
| NCT07432295 | Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2) | recruiting | Phase 2 | 180 | I-Mab Biopharma US LimitedINDUSTRY | 3 | May 14, 2026 | clinicaltrials |
| NCT07012798 | FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma | recruiting | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 13, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 9, 2026source: clinicaltrials